Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Acadia Healthcare (ACHC) and Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Analyst Ratings
H.C. Wainwright Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $42
Promising Potential of Bicara Therapeutics' Ficerafusp Alfa: A Buy Rating Supported by Innovative Dual-Targeting and Positive Trial Results
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $47
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36
TD Cowen Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $36
TD Cowen Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
Promising Prospects for Bicara Therapeutics: Buy Rating on Ficerafusp's Innovative Approach
Rodman & Renshaw Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $48
Bicara Therapeutics Initiated at Overweight by Morgan Stanley
Bicara Therapeutics Analyst Ratings
TD Cowen Initiates Bicara Therapeutics(BCAX.US) With Buy Rating
Stifel Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $47
Morgan Stanley Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $35
Bicara Therapeutics: A Buy Rating on Promising Clinical Progress and Financial Fortitude
No Data